Steris

STE Health Care Market cap $20.8B as of Sep 14, 2026 16:00 ET S&P 500

Q1 FY27 Apr 1 – Jun 30, 2026 reported Aug 7, 2026

Revenue$1.49B +7% year over year

Gross profit$0.68B 46% margin

Operating profit$0.29B 19% margin

Net profit$0.20B 13% margin

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q1 FY27 (period ends Jun 30, 2026).
Item	Value	Share of revenue	Year over year
Revenue	1.49	100%	+7%
Healthcare	1.05	70%	+8%
Applied sterilization	0.30	20%	+6%
Life science	0.15	10%
Cost of revenue	−0.81	54%
Gross profit	0.68	46% margin	+1pp
R&D	−0.03	2%	+0pp
SG&A	−0.37	25%	−1pp
Operating profit	0.29	19% margin	+1pp
Interest & other costs	−0.01
Tax	−0.07
Net profit	0.20	13% margin	+1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q4 FY26 (period ends Mar 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	1.59	100%	+7%
Healthcare	1.14	72%	+7%
Applied sterilization	0.29	18%	+6%
Life science member	0.16	10%	+9%
Cost of revenue	−0.89	56%
Gross profit	0.70	44% margin	+1pp
R&D	−0.03	2%	+0pp
SG&A	−0.35	22%	+0pp
Operating profit	0.32	20% margin	+5pp
Interest & other costs	−0.01
Tax	−0.08
Net profit	0.22	14% margin	+4pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY26 (period ends Dec 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	1.50	100%	+9%
Healthcare	1.06	71%	+9%
Applied sterilization	0.29	19%	+11%
Life science	0.15	10%	+7%
Cost of revenue	−0.84	56%
Gross profit	0.66	44% margin	−1pp
R&D	−0.03	2%	+0pp
SG&A	−0.35	24%	−1pp
Operating profit	0.27	18% margin	+0pp
Interest & other costs	−0.02
Tax	−0.06
Net profit	0.19	13% margin	+0pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Sep 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	1.46	100%	+10%
Healthcare	1.03	71%	+9%
Applied sterilization	0.28	19%	+10%
Life science	0.15	10%	+13%
Cost of revenue	−0.81	56%
Gross profit	0.65	44% margin	+1pp
R&D	−0.03	2%	+0pp
SG&A	−0.35	24%	−1pp
Operating profit	0.27	18% margin	+2pp
Interest & other costs	−0.01
Tax	−0.06
Net profit	0.19	13% margin	+2pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Jun 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	1.39	100%	+9%
Healthcare	0.98	70%	+8%
Applied sterilization	0.28	20%	+13%
Life science member	0.14	10%	+5%
Cost of revenue	−0.76	55%
Gross profit	0.63	45% margin	+0pp
R&D	−0.03	2%	+0pp
SG&A	−0.36	25%	−1pp
Operating profit	0.25	18% margin	+3pp
Interest & other costs	−0.02
Tax	−0.05
Net profit	0.18	13% margin	+1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Mar 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	1.48	100%	+4%
Healthcare	1.06	71%	+5%
Applied sterilization	0.27	19%	+9%
Life science member	0.15	10%	−7%
Cost of revenue	−0.84	57%
Gross profit	0.64	43% margin	+2pp
R&D	−0.03	2%	+0pp
SG&A	−0.33	23%	+0pp
Other	−0.06	4%	+0pp
Operating profit	0.22	15% margin	+0pp
Interest & other costs	−0.02
Tax	−0.05
Net profit	0.15	10% margin	+10pp

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q1 FY27 Apr 1 – Jun 30, 2026 reported Aug 7, 2026 Operating margin 19% Net profit $0.20B	Apr 1 – Jun 30, 2026	Aug 7, 2026	$1.49B	+7%	19%	$0.20B	13%
Q4 FY26 Jan 1 – Mar 31, 2026 reported May 29, 2026 Operating margin 20% Net profit $0.22B	Jan 1 – Mar 31, 2026	May 29, 2026	$1.59B	+7%	20%	$0.22B	14%
Q3 FY26 Oct 1 – Dec 31, 2025 reported Feb 6, 2026 Operating margin 18% Net profit $0.19B	Oct 1 – Dec 31, 2025	Feb 6, 2026	$1.50B	+9%	18%	$0.19B	13%
Q2 FY26 Jul 1 – Sep 30, 2025 reported Nov 6, 2025 Operating margin 18% Net profit $0.19B	Jul 1 – Sep 30, 2025	Nov 6, 2025	$1.46B	+10%	18%	$0.19B	13%
Q1 FY26 Apr 1 – Jun 30, 2025 reported Aug 7, 2025 Operating margin 18% Net profit $0.18B	Apr 1 – Jun 30, 2025	Aug 7, 2025	$1.39B	+9%	18%	$0.18B	13%
Q4 FY25 Jan 1 – Mar 31, 2025 reported May 29, 2025 Operating margin 15% Net profit $0.15B	Jan 1 – Mar 31, 2025	May 29, 2025	$1.48B	+4%	15%	$0.15B	10%